Table 5.
Cox proportional univariate and multivariate analysis of variables correlated with overall survival.
| Variables | Univariate | Multivariate | ||
|---|---|---|---|---|
| HR (95% CI) | p Value | HR (95% CI) | p Value | |
| Rural City | 0.81 (0.59–1.15) | 0.197 | 0.80 (0.58–1.12) | 0.20 |
| Age | 0.857 (0.542–1.353) | 0.507 | ||
| WHO PS < 2 | 0.538 (0.358–0.806) | 0.003 | 0.73 (0.48–1.11) | 0.15 |
| Comorbid Illness | 0.869 (0.633–1.193) | 0.387 | ||
| Secondary Cancer | 0.70 (0.42–1.16) | 0.172 | 0.65 (0.38–1.10) | 0.11 |
| No Smoking | 0.86 (0.62–1.21) | 0.402 | ||
| History of Early-Stage Breast cancer | 0.940 (0.630–1.402) | 0.760 | ||
| Primary Endocrine Resistance | 0.90 (0.60–1.33) | 0.597 | ||
| Chemotherapy prior to Fulvestrant | 0.901 (0.653–1.243) | 0.525 | ||
| Chemotherapy post fulvestrant | 0.425 (0.305–0.593) | <0.001 | 0.32 (0.23–0.47) | <0.0001 |
| Non-Visceral Metastasis | 0.701 (0.506–0.970) | 0.032 | 0.70 (0.50–0.97) | 0.03 |
| ≤2 previous therapies | 0.747 (0.544–1.026) | 0.072 | 0.76 (0.55–1.05) | 0.10 |
| Combination therapy | 0.67 (0.44–1.05) | 0.078 | ||
| Clinical Benefit | 0.574 (0.402–0.819) | 0.002 | 0.44 (0.30–0.65) | <0.0001 |